As filed with the Securities and Exchange Commission on March 28, 2024
Registration No. 333-
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM S-8
REGISTRATION STATEMENT
Under
The Securities Act of 1933
CANDEL THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)
| | |
Delaware | | 52-2214851 |
(State or other jurisdiction of incorporation or organization) | | (I.R.S. Employer Identification No.) |
117 Kendrick St Suite 450
Needham, MA 02494
(617) 916-5445
(Address, including zip code and telephone number, including area code, of Registrant’s principal executive offices)
Candel Therapeutics, Inc. 2021 Stock Option and Incentive Plan
Candel Therapeutics, Inc. 2021 Employee Stock Purchase Plan
(Full title of the plans)
Paul Peter Tak, M.D., Ph.D.
President and Chief Executive Officer
Candel Therapeutics, Inc.
117 Kendrick St Suite 450
Needham, MA 02494
(617) 916-5445
(Name, address, including zip code, and telephone number, including area code, of agent for service)
Copies to:
William D. Collins, Esq.
Finnbarr D. Murphy, Esq.
Goodwin Procter LLP
100 Northern Avenue
Boston, Massachusetts 02210
(617) 570-1000
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
| | | | | | |
Large accelerated filer | | ☐ | | Accelerated filer | | ☐ |
| | | |
Non-accelerated filer | | ☒ | | Smaller reporting company | | ☒ |
| | | |
| | | | Emerging growth company | | ☒ |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐